Chromogranin A in human disease

Advances in Experimental Medicine and Biology

Volumn 482, Issue , 2000, Pages 377-388

  O'Connor, D T ^a   Mahata, S K ^a   Taupenot, L ^a   Mahata, M ^a   Taylor, C V L ^a   Kailasam, M T ^a   Ziegler, M G ^a   Parmer, R J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A;

CONFERENCE PAPER; HEART FAILURE; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; MIXED TUMOR; NEUROENDOCRINE DISEASE; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADRENAL GLAND NEOPLASMS; ANIMALS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE; MALE; NERVOUS SYSTEM DISEASES; NEUROENDOCRINE TUMORS; PHEOCHROMOCYTOMA; PROSTATIC NEOPLASMS; RATS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034468521     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (52)

1. Vasoinhibitory activity of synthetic peptides from the amino terminus of the adrenomedullary chromogranin A
2. Chromogranin A in cerebrospinal fluid: A biochemical marker for synaptic degeneration in Alzheimer's disease?
3. Vasostatins: Vasodilators of bovine resistance arteries
4. Similarity of secretory protein I from parathyroid gland to chromogranin A from adrenal medulla
5. Chromogranin A and tumor necrosis factor alpha in chronic heart failure
6. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression
7. Plasma chromogranin A: A marker of serotonin release and of emesis associated with cisplatin chemotherapy
8. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies
9. Granins and prostate cancer
10. Chromogranin A epitopes: Clues from synthetic peptides and peptide mapping
11. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules
12. Chromogranin A in uremia: Progressive retention of immunoreactive fragments
13. Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution
14. Chromogranin A storage and secretion: Sensitivity and specificity for the diagnosis of pheochromocytoma
15. Chromogranin A in children with neuroblastoma: Serum concentration parallels disease stage and predicts survival
16. Factitious pheochromocytoma: Novel mimickry by valsalva maneuver and clues to diagnosis
17. Molecular characterization of immunoreactivities of peptides derived from chromogranin A (GE-25) and from secretogranin 11 (secretoneurin) in human and bovine cerebrospinal fluid
18. Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes
19. Novel autocrine feedback control of catecholamine release: A discrete chromogranin A fragment is a non-competitive nicotinic cholinergic antagonist
20. Chromogranin A-like immunoreactive neurites are major constituents of senile plaques
21. Plasma chromogranin A in primary hyperparathyroidism
22. Chromogranin: Widespread immunoreactivity in polypeptide hormone producing tissues and in serum
23. Adrenal medulla, catecholamines and pheochromocytoma
24. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma
25. Secretion of chromogranin A by peptide producing endocrine neoplasms
26. Chromogranin A, the major catecholamine storage vesicle soluble protein: Multiple size forms, subcellular storage and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay
27. Chromogranin A: Immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands
28. Immunoreactive chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues
29. Chromogranin A immunoreactivity in human cerebrospinal fluid: Properties, relationship to noradrenergic neuronal activity, and variation in neurologic disease
30. Heredity and the autonomic nervous system in human hypertension
31. Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia
32. Chromogranin A: Localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve
33. Human chromogranin A: Purification and characterization from catecholamine storage vesicles of pheochromocytoma
34. Rapid radioimmunoassay of circulating chromogranin A: In vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure
35. Catecholamine storage vesicle protein expression in genetic hypertension
36. Chromogranin A in malignant pheochromocytoma
37. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system
38. Pancreastatin: Biological effects and mechanisms of action
39. Increased pancreastatin-liked immunoreactivity levels in non-obese patients with essential hypertension
40. Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension
41. Diagnostic cytological features of neuroendocrine differentiated carcinoma of the breast
42. Clinical improvement in Parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid
43. Assignment of the chromogranin A locus to homologous regions on mouse chromosome 12 and rat chromosome 6
44. Endocrine cells in the human oxyntic mucosa: A histochemical study
45. Source of plasma chromogranin A elevation in gastrinoma patients
46. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments
47. Chromogranin A: Storage and release in hypertension
48. Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension
49. Chromogranin A in human hypertension: Influence of heredity
50. CSF chromogranin A-like immunoreactivity in schizophrenia: Assessment of clinical and biochemical relationships
51. Undegraded chromogranin A is present in serum and enters the endocytotic lysosomal pathway in kidney
52. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients